Dr. Paumen, CEO of Clearbridge BioMedics held several senior leadership positions in the biotech and biomedical industries prior to joining the Company. Previously, Dr. Paumen was with Life Technologies – now Thermo Fisher Scientific and led commercial efforts in Next Generation Sequencing and Genomic Medicine in Japan and the Medical Sciences business for the Asia Pacific region. Highlights include achieving Medical Device status for the company’s sequencers and RT-PCR systems.
Prior to joining Life Technologies, he was CEO at Dx Assays Pte Ltd (Singapore), a developer of Molecular Diagnostics test systems for a period of 2 years. Before joining Dx Assays, Dr. Paumen was Technical Director at Affymetrix Inc. and developed their Sales and Marketing infrastructure in Japan.
Other earlier positions include a Scientific Affairs management role at QIAGEN GmBH, overseeing worldwide clinical collaborative studies in both academia and industry and the inception of QIAGEN’s first offices in Asia.
Dr. Paumen obtained his PhD from Johannes-Gutenberg University, Germany and researched on Programmed Cell Death at the German Cancer Research Centre and Kyoto University, Faculty of Medicine, Japan.